Considering that the expression of THOP1 has been repeatedly found upregulated in cancer cells compared to normal cells, including sarcomas [15,16,17,18,19], the prodrugs have potentially increased tolerability, tumor specificity and efficacy compared to conventional doxo. This evidence concerns the gene THOP1 and sarcoma.